Diltiazem Hci
Brand Names: Diltiazem Hci Generic
Methodology & AI Transparency ⓘ
Diltiazem Hci Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: INDICATIONS & USAGE Diltiazem Hydrochloride Injection or Diltiazem Hydrochloride for Injection are indicated for the following: Atrial Fibrillation or Atrial Flutter Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter.
- 2 Real-world patient consensus: Tracked across 18 patient dosage logs with a 94% satisfaction benchmark (RxCUI 1791240).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $12.29 cash mean against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Diltiazem Hci include orthostatic hypotension (4.3%), dizziness (6.4%), headache (5.5%).
Ask our AI Specialists anything about Diltiazem Hci
Diltiazem Hci Mechanism, CYP450 Pathways & DailyMed Monograph
INDICATIONS & USAGE Diltiazem Hydrochloride Injection or Diltiazem Hydrochloride for Injection are indicated for the following: Atrial Fibrillation or Atrial Flutter Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome.
CLINICAL PHARMACOLOGY Mechanisms of Action Diltiazem inhibits the influx of calcium (Ca2+) ions during membrane depolarization of cardiac and vascular smooth muscle. The therapeutic benefits of diltiazem in supraventricular tachycardias are related to its ability to slow AV nodal conduction time and prolong AV nodal refractoriness. Diltiazem exhibits frequency (use) dependent effects on AV nodal conduction such that it may selectively reduce the heart rate during tachycardias involving the AV node with little or no effect on normal AV nodal conduction at normal heart rates.
Following administration (5 mg/mL Injection), Diltiazem Hci achieves Complete (~100%) parenteral systemic delivery for Diltiazem Hci (5 mg/mL Injection) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after diltiazem hci administration onset, governed by a Biphasic clearance with 5–12 hr terminal t½ under Diltiazem Hci maintenance terminal half-life through hepatic enzymatic processing and renal clearance proportional to creatinine clearance (diltiazem hci).
Before initiating Diltiazem Hci at 5 mg/mL Injection, clinical safety checklists rule out contraindications injectable forms of diltiazem are contraindicated in: patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker.; patients with second- or third-degree av block except in the presence of a functioning ventricular pacemaker.; patients with severe hypotension or cardiogenic shock.. Logged tolerability patterns center on dizziness (6.4% of reports), headache (5.5% of reports), fatigue (5.4% of reports).
Divalent and trivalent cations bind Diltiazem Hci intraluminally and blunt peak oral plasma concentrations.
Assess baseline hepatic panels and interacting prescriptions when starting Diltiazem Hci (calcium channel blocker).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Injectable forms of diltiazem are contraindicated in: Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker.
- Patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker.
- Patients with severe hypotension or cardiogenic shock.
Logged Side-Effect Incidence (18 Reports)
Diltiazem Hci Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diltiazem Hci)
Human clinical trial evidence for Diltiazem Hci is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Diltiazem Hci Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0935/unit (~$2.81/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $12.29 / mo | View logs ↓ |
Diltiazem Hci Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Diltiazem Hci RxNorm Concept ID | 1791240 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0935 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $12.29 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Diltiazem Hci Patient Community, Cohort Filters & Dosage Logs
Deterministic Diltiazem Hci reference combining NIH RxNorm (1791240), Medicaid NADAC ($0.0935/unit), and anonymous cohort outcomes (94% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Diltiazem Hci community threads and patient logs by age, biological sex, dosage, and treatment duration.